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Plasma levels of D-dimer are elevated in cancer patients. Activation of the extrinsic coagulation system and the ﬁbrinolytic
cascade within a tumour is thought to be related with growth, invasion and metastasis. We have investigated the relationship
between these markers of ﬁbrin metabolism, standard clinicopathological variables and serum levels of angiogenic cytokines in
three cohorts: group A (n=30) consisted of 30 healthy female volunteers, group B (n=23) of consecutive patients with
operable breast cancer and group C (n=84) of patients with untreated or progressive metastatic breast cancer. Plasma D-
dimers, ﬁbrinogen, IL-6, vascular endothelial growth factor and calculated vascular endothelial growth factor load in platelets
are clearly increased in patients with breast cancer. D-dimers were increased in nearly 89% of patients with progressive
metastatic disease. The level of D-dimers was positively correlated with tumour load (P50.0001), number of metastatic sites
(P=0.002), progression kinetics (P50.0001) and the cytokines related to angiogenesis: serum vascular endothelial growth
factor (P=0.0016, Spearman correlation=0.285), calculated vascular endothelial growth factor load in platelets (P50.0001,
Spearman correlation=0.37) and serum interleukin-6 (P50.0001, Spearman correlation=0.59). Similarly increased D-dimer
levels were positively correlated with increased ﬁbrinogen levels (P50.0001, Spearman correlation=0.38). The association
between markers of ﬁbrin degradation in patients with progressive breast cancer suggests that the D-dimer level is a clinically
important marker for progression and points towards a relation between haemostasis and tumour progression. A role of
interleukin-6, by inﬂuencing both angiogenesis and haemostasis, is suggested by these observations.
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Tumour growth is considered to be dependent on angiogenesis
(Folkman, 1990). Ongoing angiogenesis is recognized by the
presence of immature vessels, with endothelial cells displaying a
pro-coagulant phenotype (Brock et al, 1991; Zucker et al, 1998;
Benjamin et al, 1999). Among the pro-angiogenic cytokines vascu-
lar endothelial growth factor (VEGF) has spurred the most interest
(Bicknel and Harris, 1991; Carmeliet et al, 1996a, Carmeliet and
Collen, 1997).
The capacity of VEGF to increase vascular permeability is
considered to be critical (van Bruggen et al, 1999; Yano et al,
2000). Plasma and serum VEGF levels are elevated in a majority
of untreated cancer patients and these levels are predictive for
the clinically measured tumour doubling kinetics (Dirix et al,
1996, 1997). Serum VEGF levels are always much higher than plas-
ma levels (George et al, 2000). Different studies have consistently
observed a signiﬁcant correlation between platelet count and serum
VEGF of patients with different types of cancer (Mo ¨hle et al, 1997;
Salgado et al, 1999; Verheul et al, 1999; Vermeulen et al, 1999).
Systemic abnormalities of haemostasis in cancer patients have
increasingly been recognized, but whether this abnormal haemosta-
sis bears any signiﬁcance in the pathogenesis of the malignant
process remains unclear. Many coagulation factors have been found
to be either increased or depressed in plasma of cancer patients and
increased markers of ﬁbrinogen degradation are among the most
frequently observed haemostatic alterations (Murray, 1991). Several
reports have strengthened the concept of a physiological connec-
tion between activated coagulation and angiogenesis in human
cancer. Previously, the activation of coagulation in cancer was
mainly considered to be the result of increased expression of tissue
factor (TF), leading to the activation of the extrinsic coagulation
pathway (Kakkar et al, 1995). Recent data have shown that TF also
leads to increased expression of VEGF and decreased transcription
of thrombospondin, and inhibitor of angiogenesis (Zhang et al,
1994; Contrino et al, 1996; Carmeliet et al, 1996b). The activation
of the coagulation system occurs also in the perivascular region in
human cancers and contributes to tumour stroma formation, even
at a very early stage of tumorigenesis (Shoij et al, 1998; Brown et
al, 1999).
Similarly, platelet turnover is increased even in the presence of
thrombocytosis and an increased platelet number has been shown
to be predictive for shorter survival in patients with colorectal
and lung cancer (Honn et al, 1992; Monreal et al, 1998). Others
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with solid tumours (Verheul et al, 2000).
In an earlier study the serum levels of cytokine IL-6 were found
to relate with the total amount of VEGF in serum, and also with
the calculated platelet VEGF content (Salgado et al, 1999). This
is in accordance with the known thrombopoietic and VEGF up-
regulating activity of IL-6 (Clarke et al, 1996; Cohen et al, 1996).
IL-6 is considered to have direct angiogenic activity (Motro et al,
1990; Mateo et al, 1994).
We have attempted to relate levels of D-dimers with the extent of
disease and progression rate in patients with breast cancer. We
further examined in these patients whether markers of ongoing ﬁbrin
degradation showed any relation with markers of angiogenesis.
MATERIALS AND METHODS
Patients
Group A is the control group and consists of 30 female volunteers.
The 107 female patients with breast cancer are divided into two
cohorts; group B includes 23 consecutive patients with newly diag-
nosed stage I or II disease (Table 1) and group C includes 84
consecutive patients with metastatic disease, either primarily
untreated or progressive after therapy (Table 2). From these 107
(groups B+C) consecutive patients, different clinical and pathologi-
cal variables were collected; age at diagnosis, current age at
sampling time, menopausal state, disease free interval after primary
treatment, number and type of prior systemic therapies including
adjuvant treatment, histological type, hormone receptor status,
number and sites of disease (locally, lymph node and soft tissue,
liver, lung, bone, brain and other). Blood samples were collected
in group C when untreated metastatic disease was either initially
diagnosed or progression of disease was documented radiologically
and prior to the initiation of a (new) systemic therapy. For patients
in group B sampling occurred at the moment of diagnosis prior to
initiation of treatment or biopsy.
Tumour load
An estimation of the extent of disease was attempted for all group
C patients. For bony lesions a whole body technetium scan at the
time of data collection was used, with limited disease being equal
to 1–2 hot spots, moderate load implying 3–5 separate hot spots
and large tumour load more than ﬁve separate spots. For liver
involvement a standard contrast-enhanced CT-scan and for
pulmonary lesions a standard X-ray or a CT-scan were used. These
were scored for (a) small volume of disease if 510% of the esti-
mated organ volume was involved with disease, (b) moderate if
this was increased up to 10–25%, and (c) large burden was
recorded once more than one quarter of either the liver or lung
were estimated to be replaced by tumour. Two investigators scored
each patient separately. A reliable estimation of tumour load was
considered feasible in 80 patients.
Tumour progression kinetics
Tumour progression was estimated for every patient in group C, if
any measurable (in two dimensions) lesion was documented, either
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Table 1 Characteristics of Group B: 23 patients with operable breast
cancer
Number
Age, years (mean+s.d.)
Mean 56+14
Median 54
Menopausal status
Pre+peri 6
Post 17
Tumour type
IDA 19
ILA 4
Tumour differentiation
I4
II 10
III 9
Hormone receptor status (PT and/or M)
OR and/or PgR+ 14
OR7/PgR7 9
Tumour size (mm)
510 9
10–20 8
420 6
Pathological stage
Stage I 10
Stage II 13
IDA=inﬁltrating ductal adenocarcinoma; ILA=inﬁltrating lobular carcinoma;
OR=oestrogen receptor; PgR=progesterone receptor.
Table 2 Characteristics of Group C: 84 patients with stage IV breast
cancer
Number
Age, years (mean+s.d.) 59+18
Pre- and perimenopausal 32
Postmenopausal 52
Disease free interval in months (mean) 40+38
Initial diagnosis with metastasis 20
Prior treatment for metastatic disease 64
Hormonal therapy 46
Chemotherapy 18
Tumour type
IDA 72
ILA 10
ILA+IDA 2
Tumour differentiation
I5
II 25
III 54
Hormone receptor status (PT and/or M)
OR and/or PgR+ 69
OR7/PgR7 10
UNK 5
Metastases
Bone only 12
Liver only 4
Lung only 2
Locoregional only 4
Soft tissue only 4
Bone+soft tissue 22
Visceral+other 36
Number of sites involved
12 6
22 7
423 1
Tumour load (n=80)
Limited 19
Moderate 40
High 21
Tumour progression kinetics (n=58)
Doubling time 53 months 36
Doubling time 43 months 22
IDA=inﬁltrating ductal adenocarcinoma; ILA=inﬁltrating lobular carcinoma;
OR=oestrogen receptor; PgR=progesterone receptor; UNK=unknown.
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and at some point in time during the preceding 3 months. Disease
progression was considered to be rapid, when estimated tumour
doubling time (duplication of surface area) in any one lesion was
less than 3 months. In 58 of the 84 patients an estimation of the
kinetics of tumour progression was made. These were divided into
a rapid (53 months) and a slow progressive group (43 months).
Blood collection and tests
Coagulation tests Plasma was collected into a 3 ml blood
collection tube, containing trisodium (Vacutainer, Becton-Dick-
inson). Samples were prepared by centrifugation at 2200 g for
10 min. Prothrombin time (PT), partial thromboplastin time
(PTT) and ﬁbrinogen (FG) were determined on the photo-opti-
cal SYSMEX CA6000 Coagulation automate. For the PT
determination, a recombinant human tissue factor was used
and for the aPTT a phospholipid reagent with particulate acti-
vator was applied (micronized silica). Quantitative D-dimer
levels were obtained using the enzyme linked ﬂuorescent assay
(ELFA) on a mini VIDAS system (bio-Merieux). The assay
employs a quantitative sandwich enzyme immunoassay technique
combining a bound anti-D-Dimer monoclonal immunoglobulin
with an unbound enzyme labelled anti-D-dimer monoclonal
immunoglobulin. D-Dimer levels greater than 250 ng ml
71 were
considered to be elevated. All coagulation parameters are
measured on citrated plasma within 2 h of sample collection.
Whole blood collection was made by taking a venous blood
sample of 3 ml into a blood collecting tube containing EDTA
as anticoagulant.
Angiogenic cytokines Simultaneously with the previous blood
sampling, another 10 ml of venous blood was drawn into a serum
separator tube (Vacutainer, Becton-Dickinson) and allowed to
stand for 30 min at room temperature to ensure full clotting.
All samples were centrifuged at 3000 g for 5 min and the super-
natanses were aliquoted and stored at 7808C. Serum levels of
bFGF, VEGF and IL-6 were determined using three different
enzyme-linked immunosorbent assays (ELISA) (R&D Systems,
Minneapolis, MN, USA; Quantikine High Sensitivity human
FGF basic; Quantikine human VEGF; Quantikine human IL-6).
Within assay reproducibility has been tested before (Dirix et al,
1996, 1997; Salgado et al, 1999; Vermeulen et al, 1999) All
samples were run in duplicate. The upper limit of normal for
these cytokines was deﬁned by using a 95% conﬁdence limit from
the mean value obtained from healthy volunteers. For IL-6
this was 1.3 pg ml
71 for VEGF 250 pg ml
71 and for bFGF
5.0 pg ml
71.
Ethical committee
This study was approved by the local Ethical Committee and oral
informed consent was obtained.
Statistical analysis
Statistical analysis was performed with the Statview 4.51 software
application (Abacus Concepts) on an Apple Macintosh personal
computer. Spearman correlation coefﬁcients were used to examine
the association between pairs of variables. Comparison of contin-
uous variables in different subgroups were performed by Mann–
Whitney U-test or by a Kruskal–Wallis test. Relationships
between categorical variables were compared using a w
2 test. Over-
all survival was studied by Kaplan–Meier method analysis.
Univariate survival curve differences were tested for signiﬁcance
with a log-rank test. A Cox proportional hazards regression model
was used to assess the prognostic signiﬁcance of the parameters
taken in association.
RESULTS
Patients characteristics
The characteristics of the study population are listed in Tables 1
and 2. A total of 107 blood samples were collected from 107
patients (23 patients of group B, 84 of group C). The 84
patients of group C are part of a total of 140 patients treated
during that same period (8 months) with progressive disease.
Of those 140 patients, 50 were excluded because progression
became apparent within 4 weeks of chemotherapy administration.
In the same period two patients were admitted with both
progressive disease and a thrombotic event (one arterial throm-
bosis of the lower limb considered to be a tumour-related
event, one patient with deep venous thrombosis and pulmonary
embolism). Four patients were excluded because of persisting
thrombocytopenia after chemotherapy. Most tumours were inﬁl-
trating ductal carcinomas (85.7%). Only 18 patients had been
chemotherapy treated for metastatic disease. A majority of
patients (46 out of 84, 54%) was progressive under hormonal
therapy after either ovarian ablation in 12, tamoxifen in 28, or
exemestane in eight. In 20 patients sampling occurred at the
time of ﬁrst diagnosis of metastatic disease, six of these patients
were diagnosed to have metastatic disease during their initial
staging procedure for breast cancer. The extent of metastasis is
shown in detail both with regard to type and number of sites,
and including an estimation of tumour load. In the 64 patients
with treated metastatic disease, doubling times could be esti-
mated for 58 patients (90%).
Routine coagulation tests, plasma D-dimer levels and
breast cancer stage
Plasma D-dimer levels were increased in the two groups of breast
cancer patients (Tables 3 and 4). The mean D-dimer level for all
patients with breast cancer (groups B+C) was 2099+3623 ng ml
71
(median 873 ng ml
71; range 113–26009; n=107). This was signiﬁ-
cantly higher compared to the volunteer population (P50.0001).
Patients with metastatic disease (group C) had higher plasma D-
dimer levels (P50.0001). Patients in group B had elevated levels
in 7 out of 23 (30.5%) whereas in group C 75 out of 84 (89%)
had increased D-dimer levels. Within group C, D-dimer levels were
higher in patients with higher tumour load. The differences
between these three groups were all highly signiﬁcant
(P50.0001). Similarly D-dimer levels were higher in patients with
rapid progressive disease compared to the slowly progressive group.
Of the other variables number of sites (more than 2 vs 1; P=0.002)
and the presence or absence of liver metastasis (P=0.032) were
signiﬁcantly related to higher D-dimer levels. Tumour type, differ-
entiation, receptor status, menopausal status at diagnosis, prior
treatment, were not signiﬁcantly related to D-dimer level. Of all
factors examined, only D-dimer levels showed a signiﬁcant correla-
tion with both number of sites involved and an estimation of load
of disease in one of the three sites mentioned.
Fibrinogen levels were clearly higher in breast cancer patients,
and the same factors that were correlated to higher D-dimer levels,
were related to high ﬁbrinogen levels. The plasma ﬁbrinogen
levels for the entire group of 107 breast cancer patients was
382+130 mg ml
71 (median 351 mg ml
71)( P=0.05). Similarly,
within group C, high ﬁbrinogen levels were related with tumour
load (P=0.01), rapid progression (P=0.0007) and presence of liver
metastasis (P=0.03). A relation between ﬁbrinogen level with
number of sites involved was not detected, which is clearly differ-
ent from the results obtained with D-dimer levels. Furthermore, a
strong statistical correlation exists between D-dimer levels and
ﬁbrinogen (P50.0001).
Platelet counts were measured in all 107 patients with a mean
value of 240+75610
9 per ml (median 243; range 65–616610
9
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 389–395per ml). The number of platelets was not different between both
groups of breast cancer patients. Within group C however, platelet
counts were higher in the group with fast progressive disease
compared to the group with slow progressive disease. Platelet count
was not related to tumour type, differentiation, receptor status,
menopausal status at diagnosis, age at diagnosis, disease-free inter-
val, prior treatment, volume of disease, number of sites involved,
nor presence or absence of liver metastasis.
Serum IL-6, VEGF, VEGF per 10
6 platelets and bFGF and
breast cancer stage
Mean serum IL-6 levels for all 107 patients was
10.1+19.6 pg ml
71 (median 4.3; range 0.4–162.3 pg ml
71).
These levels were signiﬁcantly higher compared to the healthy
control group. Serum IL-6 levels were also more elevated in the
metastatic group compared to group B with a mean value
of respectively 12.3+21.6 pg ml
71 and 2.0+1.1 pg ml
71
(P50.0001). In the group of 58 patients with known progression
kinetics estimates, 40 patients had IL-6 levels higher than
1.3 pg ml
71. Of these 40 patients, 32 were found in the fast
progressive group and eight in the slow progressive group,
whereas patients with IL-6 levels less than 1.3 (n=9), only four
were found in the fast progressive group and ﬁve in the slow
progressive group (w
2 test; P=0.033). Within group C patients,
IL-6 levels were higher in the group of patients with liver metas-
tasis, compared to those with (only) other metastasis (P=0.007).
Serum IL-6 was also signiﬁcantly higher in patients with more
extensive disease (P=0.01).
The mean serum VEGF for both groups was 349+271 pg ml
71
(median 256 pg ml
71). In group C the mean serum VEGF was
signiﬁcantly higher than in group B patients. In group C, 47
out of 84 patients had increased serum VEGF levels, whereas only
seven out of 23 of the patients with stage I or II breast cancer had
increased serum VEGF levels (w
2 test; P=0.04). Within group C,
patients with either high tumour load, more than two sites of
metastatic deposits, or rapid progression tended to have higher
serum levels, but these differences never reached clear statistical
signiﬁcance with respective P values of 0.08, 0.09 and 0.089. A
signiﬁcant linear relationship between serum VEGF and platelet
count was observed in the entire group of breast cancer patients
(Spearman correlation=0.33; P=0.0007). The calculated VEGF load
(pg) per 10
6 was signiﬁcantly higher in the 107 breast cancer
patients compared to our controls. But similarly as for serum
VEGF, VEGF load per 10
6 platelets was signiﬁcantly higher in
patients with progressive metastatic disease. Of patients with
VEGF per 10
6 platelets higher than 1, which is the 95th percentile
for normal individuals (n=35), 29 were found in the fast progres-
sive group, whereas patients with VEGF per 10
6 platelets less than
1( n=14), only seven were found in the fast progressive group
(w
2 test; P=0.019). Serum bFGF had a mean level
10.11+42.31 pg ml
71 (median 4.00; range 0.50–351.0). The
value of 10.11 pg ml
71 was however signiﬁcantly higher than
the one observed in our female control group (P=0.001). No
differences were found however in the different groups of patients
with breast cancer, or within the group of metastatic breast cancer
patients.
Relationship between markers of increased ﬁbrinogen
metabolism and angiogenic cytokines in patients with
breast cancer
In both groups of breast cancer patients plasma levels of D-
dimers are signiﬁcantly elevated compared to healthy controls.
Similarly the D-dimer levels are positively related to ﬁbrinogen
levels. Results of a more detailed correlation analysis of the
different variables from the group of 107 breast cancer patients
(group B+C) are given in Table 5. In this group sIL-6 was most
strongly correlated with plasma ﬁbrinogen, plasma D-dimers,
serum VEGF, and sVEGF per 10
6 platelets. Between D-dimer
levels and serum IL-6 (P50.0001) and similarly between plasma
ﬁbrinogen and serum IL-6 (P50.0001) a highly signiﬁcant posi-
tive correlation is observed. A statistically signiﬁcant correlation
was found between serum VEGF and IL-6 (P50.0001) and
between the calculated VEGF load per 10
6 platelets and IL-6
(P50.0001).
D-dimer levels show a strong correlation with serum VEGF
(P=0.0016), and VEGF load per 10
6 platelets (P50.0001).
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 3 Coagulation tests, plasma D-dimer levels and angiogenic cytokines
Group A Group B Group C
(n=26) (n=23) (n=84) *P
Fibrinogen (mg dl
71)
Mean+s.d. 230+55 315+57 400+138 0.0033
4ULN (400 mg dl
71) (%) 0 (0%) 1 (4%) 34 (40%)
PT (%)
Mean+s.d. 99.1+1 99.4+1.5 97.3+11.6 NS
Platelet count (610
9 per ml)
Mean+s.d. 247+53 257+45 254+89 NS
White cell count (610
6 per ml)
Mean+s.d. 6388+1364 6523+1322 6892+2868 NS
D-dimer (ng ml
71)
Mean+s.d. – 436+327 2565+3978 50.0001
4ULN (250 ng ml
71) (%) 0 (0%) 7 (30.5%) 75 (89%)
Serum VEGF (pg ml
71)
Mean+s.d. 105+74 207+130 386+286 0.0046
4ULN (500 pg ml
71) (%) 0 (0%) 7 (30.5%) 47 (56%)
VEGF load (pg per 10
6 platelets)
Mean+s.d. 0.41+0.26 0.8+0.5 1.6+1.2 0.0012
4ULN (1 pg per 10
6 platelets) (%) 0 (0%) 5 (21%) 48 (57%)
Serum IL-6 (pg ml
71)
Mean+s.d. 0.5+0.4 2.0+1.1 12.3+21.6 50.001
4ULN (1.3 pg ml
71) (%) 0 (0%) 4 (17%) 60 (72%)
ULN=upper limit of normal; *P-values relate to the differences between group B and C.
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In univariate analysis in overall survival (OS) studies, DD level was
a prognostic parameter with high concentrations being associated
with worse survival (Figure 1). Tumour differentiation, hormone
receptor status, stage at presentation, number of sites involved,
presence of visceral disease, serum IL-6, plasma VEGF, serum ﬁbri-
nogen were also prognostic parameters. For Cox multivariate
analysis in OS studies, only DD, ﬁbrinogen and presence of visceral
disease remained signiﬁcant.
DISCUSSION
Tumour expansion depends on the proliferation characteristics of
the tumour cells and the interaction with different stromal cells
and supportive tissue. This stromal remodelling utilizes two
intrinsically related physiological mechanisms, both ﬁrmly inhib-
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Table 4 Changes in coagulation parameters and angiogenic cytokines in MBC patients
PLT=platelets 10
9 per ml; Fb=ﬁbrinogen mg mg
71; D-D=D-dimer ng ml
71; sIL-6=serum interleukin-6 pg ml
71; sVEGF=serum VEGF pg ml
71; VEGF: per 10
6 platelets=pg per
10
6 platelets; 53=doubling time less than 3 months; 43=doubling time in excess of 3 months.
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ﬁbrinolysis and the process of angiogenesis. Tissue markers of
ﬁbrinolysis, mainly the levels of tissue-type (tPA) and uroki-
nase-type (uPA) plasminogen activators, have prognostic
signiﬁcance in patients with localized and metastatic breast
cancer (Solomayer et al, 1997). In patients with both non-small
cell and small cell lung cancer, increased plasma D-dimer levels
were shown to be predictive for a worse clinical outcome (Tagu-
chi et al, 1997). Similarly in patients with primary colorectal
cancer, D-dimers predicted for more advanced stage of disease
and worse prognosis (Oya et al, 1998). Plasma D-dimer levels
predict for the presence of lymph node involvement in patients
with operable breast cancer (Blackwell et al, 2000). This analysis
of D-dimer levels in breast cancer patients is taken a step further
in this study by investigating their signiﬁcance in patients with
documented metastatic and progressive disease. The D-dimers
were found to be increased in 75 of 84 (89%) of these patients.
The mean level of D-dimers in this population was in the range
of 2.5 mgm l
71. Increased levels were not shown to be related
with histological subtype, hormone receptor status, disease-free
interval, number and type of prior treatment for metastatic
disease, or patient age. However, load of disease (P50.0001),
clinical progression rate (P50.0001), number of involved sites
(P=0.04), and presence of liver metastasis (P=0.032) were related
to increased D-dimers. Furthermore increased D-dimers were
predictive of a worse prognosis both in univariate and multivari-
ate analysis. Fibrinogen levels were signiﬁcantly increased and
showed a strong positive correlation with D-dimers. This suggests
that in unselected breast cancer patients, ﬁbrinogen is actively
being converted into ﬁbrin and that ﬁbrinolysis results in
increased D-dimer levels. As these ﬁbrin degradation products
are related to the clinically measured growth rate, they might
be in part a reﬂection of ongoing ﬁbrinogen metabolism within
the actively remodelled tumour stroma. Because the amount of
these degradation products is the only parameter to be strongly
related to both tumour bulk and the number of involved sites, it
seemed justiﬁed to consider D-dimer levels in this setting as a
marker for the disease load.
In breast cancer patients serum IL-6 has been shown to
correlate with increasing numbers of involved sites, presence
of liver metastasis, and disease progression. Serum IL-6 was
an independent prognostic factor in a multi-variate analysis in
patients with metastatic disease (Zhang and Adachi, 1999). In
60 of the 84 (72%) patients with metastatic disease serum IL-
6 was increased. As in the series by Zhang and Adachi
(1999) serum levels of IL-6 were higher in patients with liver
metastases. Because IL-6 has both a thrombopoietic and a
VEGF upregulating activity, it was postulated that serum VEGF
might be inﬂuenced by IL-6 (Cohen et al, 1996; Mo ¨hle et al,
1997). A positive correlation was shown to exist between serum
IL-6 levels and serum VEGF and the calculated load of VEGF
per 10
6 platelets (Salgado et al, 2000). These observations are
conﬁrmed in this group of patients, both between IL-6 and
serum VEGF and between IL-6 and the calculated load of
VEGF per 10
6 platelets, corroborating the potential role of IL-
6 on the expression of VEGF in platelets. This study now
extends the interrelationships of serum IL-6 with ﬁbrinogen
and D-dimer levels. On the other hand, serum IL-6 is less
inﬂuenced by the number of organs involved, but is inﬂuenced
by both volume of disease, and even more so it is a critical
predictor of progression kinetics (P=0.01) which is in accor-
dance with earlier studies (Zhang and Adachi, 1999). Serum
IL-6 seems to inﬂuence both sVEGF and sVEGF per platelets,
as well as plasma ﬁbrinogen and D-dimer levels. Serum IL-6
levels are not different between the slow and rapidly growing
group, but the distribution of patients with high and low serum
IL-6 levels was signiﬁcantly related with progression kinetics. IL-
6 might be a critical component of VEGF expression locally at
the site of a growing tumour, but furthermore increasing the
amount VEGF stored in platelets. The earlier observations on
the relationship between serum VEGF and platelet count are
conﬁrmed. Patients with high calculated VEGF per pl, above
the 95th percentile of healthy adults, tend to be in the fast
progressive group, whereas patients with low VEGF per pl tend
to be in the slowly progressive group. These data suggest that
platelets might contribute to angiogenesis, by transporting
increased amounts of VEGF to sites selected by a pro-coagulant
environment, c.q. areas of active angiogenesis similarly to the
contribution of platelets in wound healing (Knighton et al,
1982).
If one assumes that active coagulation also occurs extravascu-
larly and contributes to stromal remodelling, then the observed
correlations between the cytokine levels, ﬁbrin split products
and tumour kinetics, suggest that as new microvessels develop,
they are rendered more permeable for large molecules by VEGF,
either locally produced or delivered by platelets, enabling a shift
towards the extravascular compartment of plasma molecules like
plasminogen and ﬁbrinogen. Extravasated ﬁbrinogen is then
converted by the tissue-factor activated extrinsic coagulation
pathway to cross-linked ﬁbrin. The presence of active plasmin
in the tumour stroma cleaves ﬁbrin into a number of degrada-
tion products.
In conclusion this study extends the signiﬁcance of increased
plasma D-dimers as a predictor for more rapid tumour growth,
the presence of more widespread disease and for shorter survi-
val in breast cancer patients. It also suggests an interaction
between the coagulation system and the mediators of angiogen-
esis and the role of interleukin-6 deserves further investigations.
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Table 5 Interrelations between coagulation and angiogenesis markers
PLT FN D-D sIL-6 sVEGF sV/pl sbFGF WCC
PLT 0.25 0.33 0.43
FN 0.38 0.61 0.43 0.37
D-D 0.59 0.285 0.37
s-IL6 0.59 0.43 0.59
sVEGF 0.24
sV/pl
sbFGF
PLTs=platelets; FN=ﬁbrinogen; sIL-6=serum interleukin-6; sVEGF=serum vascular
endothelial growth factor; sV/pl=serum VEGF per 10
6 platelets; sbFGF=serum beta
ﬁbroblast growth factor; WCC=total white blood cell count. Numbers represent
those Spearman correlations with a P-value 50.05.
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Figure 1 Overall survival (days) in 84 patients with metastatic breast
cancer according to D-dimer levels.
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